

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Malik Fady Ibrahim</u>			2. Issuer Name and Ticker or Trading Symbol <u>CYTOKINETICS INC [CYTK]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ X <u>EVP Research & Development</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>03/06/2023</u>			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
<u>350 OYSTER POINT BLVD</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	<u>CA</u>	<u>94080</u>						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
<u>Common Stock</u>	<u>03/06/2023</u>		<u>A⁽¹⁾</u>		<u>40,000</u>	<u>A</u>	<u>\$0</u>	<u>175,183</u>	<u>D</u>	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
<u>Incentive Stock Option (Right to Buy)</u>	<u>\$39.13</u>	<u>03/06/2023</u>		<u>A⁽²⁾</u>		<u>2,555</u>		<u>04/06/2023</u>	<u>03/06/2033</u>	<u>Common Stock</u>	<u>2,555</u>	<u>\$0</u>	<u>2,555</u>	<u>D</u>	
<u>Non-Qualified Stock Option (Right to Buy)</u>	<u>\$39.13</u>	<u>03/06/2023</u>		<u>A⁽²⁾</u>		<u>77,445</u>		<u>04/06/2023</u>	<u>03/06/2033</u>	<u>Common Stock</u>	<u>77,445</u>	<u>\$0</u>	<u>77,445</u>	<u>D</u>	

Explanation of Responses:

- Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant.
- This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027.

/s/ John Faurescu, attorney-in-
fact for Dr. Malik 03/07/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.